14 September 2020
Visiongain has published a new report on Vaccines Sales Market Report : Forecasts by Disease Type (Viral Diseases, Bacterial Diseases), Viral Diseases (Hepatitis, Influenza, Human Papillomavirus, Measles/Mumps/Rubella, Rotavirus, Other Viral Diseases), Bacterial Disease (Pneumococcal Disease, Meningococcal Disease, Diphtheria/Tetanus/Pertussis, Other Bacterial Disease), Type of Vaccines (Recombinant/Conjugate/Subunit, Inactivated, Live Attenuated, Toxoid), Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, Other Distribution Channel), Age Group (Paediatrics, Adults, Other Age Groups), Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa), Competitive Landscape PLUS COVID-19 Impact Analysis and Profiles of Leading Vaccines Sales Companies.
Global vaccines market was valued at US$ xx billion in 2019 and is projected to reach at a market value of US$ xx billion by 2030. Global market is expected to grow at a CAGR of xx% during the forecast period 2020-2030. The market is estimated to grow at a CAGR of xx% in the first half period 2020-2025 and is projected to grow at CAGR of xx% in the other half period 2025-2030.
Vaccine Development and Distribution Amid the COVID-19 Pandemic
More than 200 countries worldwide are now affected by the COVID-19 pandemic. It has pressured manufacturers to increase manufacturing capacity and to increase the supply of products and other commodities. The pandemic stopped UNICEF, the WHO, the PAHO and other regular immunisation programmes. According to UNICEF, the end of measles / rubella immuna campaigns, polio, meningococcal disease, DTP and many other antigene campaigns was reported by 99 countries in May 2020.
The suspension and decline in immunisation campaigns caused a significant amount of damage to medical systems by making the population more susceptible of deadly antigens. The result is that the mortality rate is higher. This would have far worse consequences than the pandemic itself. GAVI reports that the cease-fire will mean that around 13.5 million people from the least developed countries will not be immunised. Further, a reduction in the provision of pneumococcal vaccine may lead to higher mortality rates due to the prevalence of pneumococcal disease.
This report forecasts that the global vaccine market is expected to grow steadily during the forecast period from 2020 to 2030. This will be driven by an ageing population and an increase in the incidence of chronic diseases that increase the risk of infection in human immune systems. Furthermore, as your economies become prosperous, your spending on health care increases, the demand from emerging markets will increase. The travel industry will also help sustain growth on the vaccine market, with higher revenues from the adult vaccine subservice resulting from increased awareness about vaccinating benefits for a country's workforce.
As treatment options become more innovative, businesses will strive to remove the cold chain from their supply logistics, cut costs, and make it easier to supplies vaccines in different climates and regions, the future of the human vaccine market looks very promising. A number of innovative vaccines are on the market in the pipeline. These vaccines are progressive improvements in vaccine efficacy, coverage through more disease strains and viable therapy against previously untreatable illnesses. This will help address a larger group of people with different health requirements, thereby increasing access and coverage of vaccinations.
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general. The growth will highlight the importance of vaccines to the global population's health and the potential advantages for the global economy between 2020 and 2030.
Rising Awareness of Immunization
The vaccine market is growing due to increasing disposable incomes and the rising awareness of the benefits of vaccination. Several foundations provide funding for vaccinations for people and children in poor countries. Some major organizations, which are working in the fields of vaccination and immunization are GAVI Alliance, the U.S. Centers for Disease Control and Prevention (CDC), the Bill & Melinda Gates Foundation, UNICEF, PATH, U.S. Agency for International Development (USAID) and United Nations Foundation for International Partnerships (UNFIP). As per the WHO, immunizations are saving an estimated two to three million lives a year from diphtheria, tetanus, pertussis (whooping cough), and measles. According to an estimate from WHO, 1.5 million lives can be saved by improving global vaccination coverage. In 2016, about 86% of infants (115 million infants) received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine. Due to this, 130 countries had reached to 90% coverage of the DPT3 vaccine.
The outbreak of COVID-19 has reduced vaccine acceptance considerably. In low- and middle-income countries there was a relatively slower rate of vaccination. However, due to the rise in R&D investment against diseases, the market is likely to witness a growth in 2020. In addition, potential products are expected to be launched to contribute to market growth in the prediction period. Multiple potential candidates in the vaccine industry such as Pfizer, Johnson and Johnson are manufactured by pharmaceutical companies as well as other prominent players. Some of the companies operating in this industry are AstraZeneca, Bavarian Nordic, Bayer, BiondVax, Bristol-Myers Squibb, Eli Lilly, Emergent BioSolutions Inc., Fresenius, GlaxoSmithKline (GSK), Johnson & Johnson, Merck & Co., Pfizer, Roche, Sanofi Pasteur, and Takeda among other prominent players.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.